Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.7 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.
Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 260 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Russia Investments (DRI) is a company formed by U.S.-based life sciences venture capital firm Domain Associates to help foster innovation in the Russian health sciences sector. DRI plays a crucial role in Domain’s unique strategic collaboration with Rusnano.
Anti-cancer drugs are supplied to Russia without disruptions
06 February 2023
Russia’s government will allow import of unregistered biomedical cellular products
06 February 2023
Cell therapy biotech shifts focus to UK, makes deep cuts to US headcount
03 February 2023
Murashko: “The situation with the production of pharmaceutical substances for antibiotics is stable”
03 February 2023